 |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
| Table 3. HIV-infected patients currently prescribed antiretroviral therapy by data source and insurance status*
|
|
|
|
|
View PDF
|
|
Data in Tables 3-5 are based on the following analyses:
- Among patients eligible according to guidelines in place in 1999 (2), what is the proportion of patients prescribed ART in ASD in 1999 and SHDC in 1998?
- In SHAS, among patients interviewed in 1999 with CD4 <500 cells/µL, what is the proportion of patients who reported taking ART at the time of their interview?
|
 |
|
|
|
|
|
|
|
|
|
|
|
| Data Source |
Total |
|
Private |
|
Public |
|
No Insurance |
| % |
Treated/
Eligible |
% |
Treated/
Eligible |
% |
Treated/
Eligible |
% |
Treated/
Eligible |
| ASD |
83 |
3,098/3,751 |
|
90 |
1,064/1,184 |
|
80 |
1,642/2,054 |
|
76 |
392/513 |
| SHDC Site A |
86 |
208/242 |
92 |
97/105 |
85 |
88/104 |
71 |
27/38 |
| SHDC Site B |
86 |
147/171 |
93 |
41/44 |
87 |
150/172 |
84 |
46/55 |
| SHDC Site C |
88 |
219/244 |
92 |
76/83 |
91 |
119/131 |
70 |
23/33 |
| SHAS* |
86 |
986/1153 |
94 |
164/175 |
86 |
613/715 |
79 |
209/263 |
|
|
|
|
*Persons with unknown insurance status were not included.
|
- Overall, 83–88% of eligible patients were currently prescribed ART.
- Receipt of antiretroviral therapy was greatest among eligible patients with private insurance, followed by patients with public insurance compared with those with no insurance for all data sources.
- A lower proportion of eligible patients in ASD received antiretroviral therapy from public providers compared with SHDC and SHAS.
- Similar proportions of patients with private insurance in ASD, SHDC and SHAS received antiretroviral therapy.
- Proportions of patients with no insurance receiving antiretroviral therapy varied among studies and among SHDC sites.
- Data from the MOPTB study were not available for this question.
|
|
|
|
|
|
|
|
|
|
